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Abstract
Background: Loss of BIN1 tumor suppressor expression is abundant in human cancer and its frequency
exceeds that of genetic alterations, suggesting the role of epigenetic regulators (DNA methylation). BIN1
re-expression in the DU145 prostate cancer cell line after 5-aza-2'-deoxycytidine treatment was recently
reported but no methylation of the BIN1 promoter CpG island was found in DU145.
Methods: Methylation-sensitive arbitrarily-primed PCR was used to detect genomic loci abnormally
methylated in breast cancer. BIN1 CpG island fragment was identified among the differentially methylated
loci as a result of direct sequencing of the methylation-sensitive arbitrarily-primed PCR product and
subsequent BLAST alliance. BIN1 CpG island cancer related methylation in breast and prostate cancers
was confirmed by bisulphite sequencing and its methylation frequency was evaluated by methylation
sensitive PCR. Loss of heterozygosity analysis of the BIN1 region was performed with two introgenic and
one closely adjacent extragenic microsatellite markers.BIN1 expression was evaluated by real-time RT-
PCR.
Results: We have identified a 3'-part of BIN1 promoter CpG island among the genomic loci abnormally
methylated in breast cancer. The fragment proved to be methylated in 18/99 (18%) and 4/46 (9%) breast
and prostate tumors, correspondingly, as well as in MCF7 and T47D breast cancer cell lines, but was never
methylated in normal tissues and lymphocytes as well as in DU145 and LNCaP prostate cancer cell lines.
The 5'-part of the CpG island revealed no methylation in all samples tested. BIN1 expression losses were
detected in MCF7 and T47D cells and were characteristic of primary breast tumors (10/13; 77%), while
loss of heterozygosity was a rare event in tissue samples (2/22 informative cases; 9%) and was ruled out
for MCF7.
Conclusion: BIN1 promoter CpG island is composed of two parts differing drastically in the methylation
patterns in cancer. This appears to be a common feature of cancer related genes and demands further
functional significance exploration. Although we have found no evidence of the functional role of such a
non-core methylation in BIN1 expression regulation, our data do not altogether rule this possibility out.
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Background
BIN1 (Bridging integrator 1) is a ubiquitous adaptor pro-
tein with the features of a tumor suppressor mediating
apoptosis by c-MYC [1]. The BIN1 gene is located on chro-
mosome 2q14 within a region reported to be deleted in
30% to 40% of breast carcinomas [2]. Complete or partial
losses of BIN1 contained in this region in breast and pros-
tate cancers have been reported [3,4]. Structural analysis
of the human BIN1 gene [5] has promoted characteriza-
tion of its molecular pathology in cancer. Notwithstand-
ing the findings of genetic alterations, including allelic
deletions, of BIN1 in breast cancer (BC), their frequencies
are not sufficient to be responsible for all the cases of
BIN1 losses occurring at the level of protein and/or mes-
sage, suggesting a role for epigenetic factors [3]. As far as
BIN1 promoter contains a CpG island [5], DNA methyla-
tion events that affect promoter activity offer a likely
mechanism for epigenetic alteration in cancer. This sug-
gestion is supported by the study of genes reactivation
after treatment of prostate cancer cell lines with 5-aza-2'-
deoxycytidine, in which reactivation of BIN1 was detected
in the DU145 cells [6]. Although this finding suggests an
epigenetic mechanism of BIN1  inactivation, bisulphite
sequencing of the corresponding CGI had demonstrated
"low" methylation. Methylation-specific PCR on the sam-
ples of primary tumors had not been performed [6]. By
methylation-sensitive arbitrarily-primed PCR (MSe-AP-
PCR) we have detected abnormal methylation of a frag-
ment of BIN1 promoter region CGI in BC and studied its
methylation patterns in primary breast and prostate can-
cer samples as well as in the MCF7 and T47D BC cell lines
and DU145 and LNCaP prostate cancer cell lines.
Methods
Ninety-nine paired (tumor/control) primary breast cancer
and 46 primary prostate cancer samples were obtained
from the Blokhin Cancer Research Center and Gertsen
Moscow Oncology Research Institute and frozen at -70°
until use. MCF7 cells were cultured in minimum essential
medium (Eagle) with 2 mM L-glutamine, 10% fetal
bovine serum (all from HyClone, USA), 0.1 mM non-
essential amino acids, 1 mM sodium pyruvate, 100 u/ml
penicillin, 100 ug/ml streptomycin, supplemented with
0.01 mg/ml bovine insulin (all from Invitrogen, USA).
T47D cells were cultured in RPMI 1640 medium with 2
mM L-glutamine, 10% fetal bovine serum (all from
HyClone, USA), 1.0 mM sodium pyruvate, supplemented
with 0.2 Units/ml bovine insulin (all from Invitrogen,
USA). DU145 cells were cultured in DMEM (Gibco, USA)
supplemented with 10% fetal bovine serum (HyClone,
USA). LNCaP cells were cultured in RPMI (Gibco, USA)
supplemented with 10% fetal bovine serum (HyClone,
USA) and 5% heat-inactivated horse fetal serum (Gibco,
USA). After reaching the confluent cells were washed with
D-PBS and detached by Trypsin-EDTA (HyClone, USA).
Collected cells were used for DNA, RNA isolation.
DNA extraction was performed by standard phenol/chlo-
roform method after proteinase K treatment of the tissues
(cells). Screening for CpG islands differentially methyl-
ated in tumor and control sample pairs was performed by
the methylation-sensitive arbitrarily-primed PCR (MSe-
AP-PCR) described in [7] with the only exclusion that the
primers were not radioactively labeled. MSe-AP-PCR frag-
ments were run in nondenaturing polyacrylamide gels,
stained by silver nitrate, excised, reamplified, and under-
went direct sequencing on the ABI310 analyser (Applied
Biosystems, USA) after HpaII digestion. Genomic loca-
tions of the differentially methylated fragments were iden-
tified by BLAST analysis and PCR primers directed to the
corresponding regions were designed (table 1). Loss of
heterozygosity (LOH) analysis of the BIN1 region was per-
formed with two introgenic and one closely adjacent
extragenic microsatellite markers (table 1). Methylation
sensitive PCR (MSe-PCR) and methylation specific
sequencing protocols were described previously [8]; corre-
sponding primer sets used in this study are listed in table
1 and their relative positions are depicted in Fig. 1.
RNA extraction was done with the Ribosole A kit (Inter-
labservice, Russia). Extracted total RNA underwent DNAse
(Promega, USA) treatment at 37°C for 10 min with sub-
sequent DNAse inactivation at 65°C for 5 min. Reverse
transcription (RT) reaction was performed with the High
Capacity cDNA Archive Kit (Applied Biosystems, USA).
Real-time RT-PCR relative quantification of BIN1 expres-
sion in tumor/control pairs was performed on the ABI
PRIZM 7000 SDS (Applied Biosystems, USA) with the
provided TaqMan expression assays (BIN1, target,
Hs00184913m1; 18s rRNA, endogenous control,
Hs99999901s1; according to the Applied Biosystems Taq-
Man Gene Expression Assays nomenclature).
Results
We have identified the BIN1  promoter CGI fragment
among those differentially methylated in BC and mor-
phologically intact tissues revealed by MSe-AP-PCR. After
direct sequencing of the MSe-AP-PCR product MSe-PCR
primers were designed and its methylation status in con-
trol and BC samples estimated. Methylation frequency in
BC samples was determined as 18/99 (18%) for primary
tumors; methylated status was also revealed in MCF7 and
T47D cells. MSe analyses of prostate cancer samples
resulted in the methylation figures of 4/46 (9%). No
methylation was detected in control, morphologically
intact tissues and lymphocytes as well as in DU145 and
LNCaP prostate cancer cell lines.Journal of Carcinogenesis 2007, 6:9 http://www.carcinogenesis.com/content/6/1/9
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Methylation-specific sequencing of the corresponding
fragment has allowed us to evaluate the methylation sta-
tus of every CpG pair within the locus of interest and to
construct the methylation maps for 9 BC and 2 prostate
cancer samples that showed methylated status by MSe-
PCR (fig. 2, positions from +838 to +979). Of these, 7
samples demonstrated biallelic patterns of methylation of
all the CpGs contained within the fragment, while in the
rest all the CpG pairs were partially methylated which can
reflect either monoallelic status of methylation or con-
tamination of the tumor samples with normal cells.
Sequencing of 9 control samples, as well as of the DU145
and LNCaP cells revealed no methylated CpGs within the
region. Analysis of MCF7 BC cells showed biallelic pattern
of methylation of all CpG pairs within the sequenced frag-
ment, while in the T47D BC cells 5 proximal CpG pairs
demonstrated biallelic methylation and 5 distal CpG pairs
were partially methylated. (fig. 2).
BIN1 expression analysis revealed significant gene expres-
sion decrease/abrogation in 77% tumors (compared to
apparently normal adjacent counterparts, 13 pairs tested),
expression was completely arrested in the MCF7 cell line
and 6-fold decreased in T47D compared to the control
morphologically intact breast tissues (fig. 3). LOH analy-
sis using two intragenic and one closely adjacent extra-
genic markers has excluded BIN1  deletion (LOH) in
MCF7 cells by revealing the heterozygous state of the
BIN1 intron 1 trinucleotide (tcc)n repeat and of the (ca)n
repeat 3 kb distal to the gene. In T47D cells only the latter
was informative and demonstrated heterozygous state
with presumable partial LOH detected by decrease of
band intensity corresponding to one of the alleles.
Observed frequency of BIN1  LOH in primary breast
tumors was unexpectedly low: 81% (22/27) were inform-
ative for at least one of the three microsatellite markers
elaborated and only in 9% (2/22) of those allelic loss was
detected.
As far as the fragment detected as abnormally methylated
by MSe-AP-PCR is located within the 3' region (intron 1)
of BIN1 promoter CGI (fig. 1) and its methylation would
conventionally be considered not to affect gene expres-
sion, we have constructed primers directed to the 5'-end of
the same CGI in order to evaluate methylation that may
have possible functional consequences. By the results of
both MSe-PCR (30 samples) and methylation-specific
sequencing (25 samples) this part of the CGI appeared to
be completely unmethylated in tumor samples, in MCF7,
T47D, DU145, LNCaP cell lines and in 10 control sam-
ples.
Discussion
Altered expression of the tumor suppressor BIN1 in vari-
ous cancers had been previously reported in a number of
Structure of the BIN1 gene 5'-region and fragments of the  BIN1 promoter CGI analyzed in this study, designated by the  primer names (see table 1) Figure 1
Structure of the BIN1 gene 5'-region and fragments of the 
BIN1 promoter CGI analyzed in this study, designated by the 
primer names (see table 1). 0.9 kb promoter corresponds to 
the region sufficient for basal transcription of BIN1 [5]. 5'-
UTR is colored black.
Table 1: Primers used in the study.
Primer designation Primer sequence Location Type of analysis Ann. t, C° MgCl2, mM Product size, bp
MSe1-F tgctccaggctcttctcaggc BIN1 promoter CGI, see Fig. 1 MSe PCR 61 1.5 255
MSe1-R ggagaacgaaagtggagaagc
MSe2-F ggggctccgggcgcgttctcc 69 1.0 606
MSe2-R actgcccatctctgccatcgc
MSp1-F gggaaaggaaatttaatttttttt MSp sequencing 59 1.0 218
MSp1-R aataataaccctcaactctccaaac
MSp2-F ggataataagttgttttttaaagggttatt 58 1.0 212
MSp2-R ctccacctaatctcctttcctaaat
BIN1-CA1F cccgattttcattcaggtgtt BIN1 intron 5 LOH 60 1.5 ~210
BIN1-CA1R agttccgagtttgatgccagc
BIN1-CA2F cttctacaccttccacaatca 3 kb distal to BIN1 60 1.5 ~130
BIN1-CA2R attcctttcctgtccctttgg
BIN1-tccF ccccaccccacaacctgaagt BIN1 intron 1 60 1.5 ~200
BIN1-tccR tccctgtgtttcctggctaagJournal of Carcinogenesis 2007, 6:9 http://www.carcinogenesis.com/content/6/1/9
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papers. Sakamuro et al. reported significant reduction or
complete loss of its expression in 14/27 BC cell lines
including MCF7 and T47D as well as in 3/6 primary breast
tumors by Northern analysis [1]. Complete or partial loss
of BIN1 was reported in 6/6 estrogen receptor-positive
and estrogen receptor-negative breast carcinoma cell lines
and in 30/50 (60%) samples of malignant breast tissue
analyzed by immuno-histochemistry or RT-PCR [3]. BIN1
mRNA was decreased in 25%, and lost in 67% of 24 breast
cancer specimens in the study of Deng et al. [9]. RNA and
immunohistochemical analyses indicate that BIN1  is
expressed in most primary prostate tumors, even at
slightly elevated levels relative to benign tissues, but that
it is frequently missing or inactivated by aberrant splicing
in metastatic tumors and androgen-independent tumor
cell lines [4]. Genetic causes of BIN1 inactivation in pros-
tate cancer mostly occur as a result of allelic losses [4]. The
frequency of BIN1 losses exceeds the frequency of so far
identified genetic alterations, suggesting a role for epige-
netic factors [3]. One of these is BIN1 mRNA aberrant
splicing detected in melanoma and prostate cancer [4,10].
Another likely mechanism for BIN1 epigenetic alteration
might be presented by DNA methylation events that affect
promoter activity [3]. The BIN1 promoter contains a CpG
island [5]; nevertheless, we failed to find any report of a
targeted methylation study of this region. Scarce informa-
tion comes from the screening studies aimed to detect typ-
ical epigenetic alterations in cancer. Thus, Lodygin et al.
report reactivation of BIN1 in one of the three prostate
cancer cell lines, DU145, after 5-aza-2'-deoxycytidine
treatment which suggested epigenetic regulation of the
gene expression by promoter methylation. Based on the
bisulphite sequencing methylation of BIN1 promoter in
DU145 was classified as low, and methylation analyses in
primary tumors have not been performed [6].
We have identified a fragment of BIN1  5'-CGI among
those differentially methylated in BC by MSe-AP-PCR. Sig-
nificant methylation levels of the corresponding region in
breast and prostate primary tumors and its methylated
status in MCF7 and T47D BC cells accompanied by a high
frequency of decreased/abrogated expression of BIN1 in
our cancer samples suggested possible involvement of
methylation in BIN1 expression regulation.
Promoter CGIs often span more than 1 kilobase, and their
methylation status is as a rule heterogeneous. Methylation
often occurs in downstream regions of the promoter CGIs,
Expression of BIN1 in BC samples and cell lines measured by  real-time RT-PCR Figure 3
Expression of BIN1 in BC samples and cell lines measured by 
real-time RT-PCR. Relative expression is shown on a loga-
rithm (lg) scale. Samples are numbered in accordance with 
our registry. MCF7 and T47D – BC cell lines.
Distribution of methylated (black circles), unmethylated (white circles) and partially methylated (grey circles) CpG pairs across  the promoter (left) and the first intron (right) parts of the BIN1 CpG island Figure 2
Distribution of methylated (black circles), unmethylated (white circles) and partially methylated (grey circles) CpG pairs across 
the promoter (left) and the first intron (right) parts of the BIN1 CpG island. *nucleotide positions were counted based on 
NCBI sequences NM_139343 and AC012508, position 1 corresponds to the 1st mRNA nucleotide.Journal of Carcinogenesis 2007, 6:9 http://www.carcinogenesis.com/content/6/1/9
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but it is believed not to repress transcription [11,12].
Thus, the CDKN2A gene promoter CGI spans the pro-
moter region and exon 1, but its transcription is only con-
sistently repressed when a 230-bp region that covers the
transcription start site is methylated [11]. RASSF1A also
contains a promoter CGI that continues into its first exon,
but methylation of a region covering the minimal pro-
moter is enough for the loss of its expression [13]. MLH1
has a large promoter CGI that initiates at nucleotide -
1,000 and extends throughout exon 1. Its methylation has
been observed in far upstream regions, but only the meth-
ylation of a 280-bp region covering the transcription start
site is correlated with transcription repression [14,15].
BIN1 promoter CGI spans 1650 bp of genomic sequence
including 5'-upstream region, exon 1 and a fragment of
intron 1 of the gene and obviously contains both pro-
moter and nonpromoter sequences. Structural and func-
tional analysis of a ~0.9 kb 5'-sequence adjacent to exon 1
had revealed that it contains consensus sites for several
transcription factors and is sufficient for basal transcrip-
tion of BIN1 [5]. As far as the promoter CGI fragment ini-
tially identified and analyzed in our study lies within
intron 1 of the gene and does not belong to the promoter,
to evaluate possible methylation of the genuine promoter
region we have designed the sets of MSe and MSp primers
directed to the corresponding locus. Surprisingly, but in
consistence with the data presented by Lodygin et al. [6],
we failed to detect its abnormal methylation even in the
tumor samples methylated throughout the 3'-part of the
promoter CGI. We suggest that BIN1 promoter CGI, sim-
ilarly to those of CDKN2A or RASSF1A genes, is com-
posed of the two functionally unequal parts, 3' being
frequently and densely methylated and 5' being lowly
methylated in cancer. This statement has two major con-
cequences. On one side, as far as we have shown that the
methylation of the 3'-part is cancer-specific, it can be elab-
orated in the development of epigenetic cancer markers
after thorough evaluation of its methylation patterns in
different types of tumors. On the other, the methylation
analysis of the 3'-part may not be used in the functional
studies (may not be taken as the evidence of expression
loss) so far, as a priori assumption is that it is not likely to
affect gene expression. It should be noted though, that the
absence of such a functional link is to be supported by fur-
ther exploration, which may altogether prove the oppo-
site. Previously the analysis of more than 30 silenced
genes and 100 non-silenced genes showed that methyla-
tion of only a relatively small 'core' region covering the
transcription start site is consistently associated with gene
silencing [16,17]. It has not yet been established, how-
ever, whether or not the core region should always con-
tain the minimum promoter and the transcription start
site [18].
Conclusion
Our study supports previously obtained data of frequent
cancer-associated loss of BIN1 expression in breast cancer.
LOH and CpG methylation analyses demonstrate that
these events, being among the most widespread causes of
genes' inactivation in cancer, are nevertheless not respon-
sible for the majority of cases of BIN1 loss in BC. Even in
the case of functional significance of the BIN1 CGI 3'-part
methylation, it would account for 18% of expression
losses only, and the frequency of LOH in our BC samples
is even lower. One possibility, which was never tested, is
that BIN1 is downregulated in BC by alternative splicing
like it is in prostate cancer and melanoma. Another one
derives from the demethylation activation assay [6] and
our methylation study on DU145 cells: reactivation of
BIN1 expression after 5-aza-2'-deoxycytidine treatment in
the cells with unmethylated status of its CGI suggests the
role for the upstream epigenetically regulated factors.
Abbreviations
BC – breast cancer; CGI – CpG island; MSe-PCR – meth-
ylation-sensitive PCR; MSe-AP-PCR – methylation-sensi-
tive arbitrarily-primed PCR.
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